Connect Biopharma Files Q1 2025 10-Q

Ticker: CNTB · Form: 10-Q · Filed: May 15, 2025 · CIK: 1835268

Sentiment: neutral

Topics: 10-Q, financials, biopharma

Related Tickers: CNTB

TL;DR

**CNTB Q1 2025 10-Q FILED: Financials updated.**

AI Summary

Connect Biopharma Holdings Ltd filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including balance sheet items like common stock and additional paid-in capital. The company's principal executive offices are located at 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130.

Why It Matters

This filing provides investors with the latest financial snapshot of Connect Biopharma Holdings Ltd, crucial for understanding its current financial health and operational status.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Connect Biopharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The conformed period of report is March 31, 2025, covering the first quarter of 2025.

What is the principal business address of Connect Biopharma Holdings Ltd?

The principal business address is 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130.

What is the SIC code for Connect Biopharma Holdings Ltd?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

When was this 10-Q filed?

This 10-Q was filed on May 15, 2025.

What are some of the balance sheet items mentioned for the period ending March 31, 2025?

The filing mentions items such as Common Stock, Additional Paid-In Capital, Accumulated Other Comprehensive Income, Treasury Stock, and Retained Earnings for the period ending March 31, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Connect Biopharma Holdings Ltd (CNTB).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing